ADMA Biologics, Inc. (NASDAQ:ADMA – Get Rating) was the recipient of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 20,250,000 shares, a growth of 25.0% from the March 15th total of 16,200,000 shares. Based on an average daily trading volume, of 2,290,000 shares, the days-to-cover ratio is presently 8.8 days.
ADMA has been the topic of several recent research reports. Zacks Investment Research raised ADMA Biologics from a “sell” rating to a “hold” rating in a report on Thursday, April 14th. StockNews.com initiated coverage on ADMA Biologics in a report on Thursday, March 31st. They set a “sell” rating on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, ADMA Biologics has a consensus rating of “Buy” and a consensus price target of $5.00.
Large investors have recently made changes to their positions in the company. ProShare Advisors LLC acquired a new position in shares of ADMA Biologics in the 4th quarter valued at about $39,000. Exane Derivatives acquired a new position in shares of ADMA Biologics in the 4th quarter valued at about $40,000. Shay Capital LLC bought a new stake in ADMA Biologics in the 4th quarter valued at about $41,000. Credit Suisse AG bought a new stake in ADMA Biologics in the 3rd quarter valued at about $40,000. Finally, Lazard Asset Management LLC bought a new stake in ADMA Biologics in the 4th quarter valued at about $55,000. 32.16% of the stock is currently owned by institutional investors.
ADMA Biologics (NASDAQ:ADMA – Get Rating) last announced its quarterly earnings data on Thursday, March 24th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. The company had revenue of $26.38 million for the quarter, compared to the consensus estimate of $26.00 million. ADMA Biologics had a negative return on equity of 61.23% and a negative net margin of 88.51%. During the same period in the previous year, the business earned ($0.20) EPS. Analysts anticipate that ADMA Biologics will post -0.31 EPS for the current year.
ADMA Biologics Company Profile (Get Rating)
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
- Get a free copy of the StockNews.com research report on ADMA Biologics (ADMA)
- 3 No-Brainer Stocks to Buy with $1000
- Rite Aid Stock is Getting Cheap Enough to Buy Here
- Analysts Reel In Netflix Targets Ahead Of Q1 Earnings
- MarketBeat Podcast: Making Money in the Red-Hot Housing Market
- Banking On Bank Of America
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.